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The Role of Ubiquitination and 
Hepatocyte Growth Factor-
Regulated Tyrosine Kinase 
Substrate in the Degradation of the 
Adrenomedullin Type I Receptor
Benoît T. Roux2, Claudia C. Bauer1, Alister J. McNeish1, Stephen G. Ward2 & Graeme S. 
Cottrell1
Calcitonin receptor-like receptor (CLR) and the receptor activity-modifying protein 2 (RAMP2) 
comprise a receptor for adrenomedullin (AM). Although it is known that AM induces internalization 
of CLR•RAMP2, little is known about the molecular mechanisms that regulate the trafficking of 
CLR•RAMP2. Using HEK and HMEC-1 cells, we observed that AM-induced activation of CLR•RAMP2 
promoted ubiquitination of CLR. A mutant (CLRΔ9KR), lacking all intracellular lysine residues was 
functional and trafficked similar to the wild-type receptor, but was not ubiquitinated. Degradation 
of CLR•RAMP2 and CLRΔ9KR•RAMP2 was not dependent on the duration of AM stimulation or 
ubiquitination and occurred via a mechanism that was partially prevented by peptidase inhibitors. 
Degradation of CLR•RAMP2 was sensitive to overexpression of hepatocyte growth factor-regulated 
tyrosine kinase substrate (HRS), but not to HRS knockdown, whereas CLRΔ9KR•RAMP2 degradation 
was unaffected. Overexpression, but not knockdown of HRS, promoted hyperubiquitination of CLR 
under basal conditions. Thus, we propose a role for ubiquitin and HRS in the regulation of AM-induced 
degradation of CLR•RAMP2.
Adrenomedullin (AM) was originally isolated from human pheochromocytoma cells and identified through its 
ability to generate cAMP in platelets1. AM is a potent vasodilatory peptide and shares homology with calcitonin 
gene-related peptide (CGRP) and together with calcitonin, amylin and adrenomedullin-2 (also known as inter-
medin) form the calcitonin family of peptides2. In contrast to CGRP, AM is mainly produced by non-nervous tis-
sues including vascular smooth muscle cells and endothelial cells. The vascular endothelium constitutes a cellular 
barrier that plays a crucial role in the maintenance of vessel integrity and controls exchange of small solutes and 
macromolecules between the intravascular and interstitial space. Increased endothelial permeability is a hallmark 
of virtually every acute inflammatory reaction. Inflammation is typified by extravasation of fluid and plasma mol-
ecules as well as inflammatory mediators through the activated endothelium. Knockout mouse models affecting 
the AM system (Adm (AM gene), Calcrl (CLR gene) and Pam (peptidylglycine α-amidating monooxygenase gene; 
the enzyme which catalyzes the COOH-terminal amidation of peptide hormones)) all result in an extreme gen-
eralized oedema suggesting a role for AM in the stabilization of the endothelial barrier function3–6. Indeed, AM 
has been shown to stabilize endothelial barrier function in vitro and be protective in rodent models of sepsis7–10. 
Intriguingly, upregulation of AM has been observed in patients with sepsis and septic shock11,12.
AM and CGRP share many common functions in the cardiovascular system, and indeed they also share a 
common receptor component, namely the G protein-coupled receptor (GPCR), calcitonin receptor-like receptor 
(CLR)13. The receptors for AM and CGRP are heterodimeric complexes, comprising CLR and a single trans-
membrane protein, receptor activity-modifying protein (RAMP). If CLR is expressed with RAMP1, they form 
a high affinity receptor for CGRP. However, if CLR is expressed with RAMP2 or RAMP3, then high affinity 
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AM receptors (AM1 and AM2 receptors, respectively) are formed13. The mechanisms that regulate CLR•RAMP1 
and CLR•RAMP3 internalization and trafficking are better understood than those regulating CLR•RAMP2. The 
duration of stimulation with CGRP, determines whether CLR•RAMP1 is degraded or recycled14. Degradation of 
CLR•RAMP1 occurs in lysosomes via an ubiquitin-independent mechanism14. The recycling of CLR•RAMP1 
depends on the cleavage of CGRP in acidified endosomes by the endosomal peptidase, endothelin-converting 
enzyme 115. The proteolytic destruction of CGRP causes dissociation of β-arrestins from the endosomal 
CLR•RAMP1 complex, leaving CLR•RAMP1 free to recycle back to the cell-surface via a Rab11-dependent 
mechanism14,15. Hepatocyte growth factor-regulated tyrosine kinase substrate (HRS, also known as HGS) is part 
of a multi-protein complex localized to endosomal membranes16,17 that regulates the trafficking, degradation 
and recycling of many GPCRs18–20 and also the ubiquitination and deubiquitination of the epidermal growth 
factor receptor21. HRS also regulates the degradation and recycling of CLR•RAMP119. In contrast to RAMP1 
and RAMP2, RAMP3 contains a PSD-95/Discs-large/ZO-1 (PDZ) homology domain in its C-terminus. These 
PDZ domains are known to alter GPCR trafficking after internalization22,23. RAMP3 has been shown to interact 
with N-ethylmaleimide-sensitive factor through its PDZ domain, which prevents CLR•RAMP3 from entering a 
degradative pathway and instead CLR•RAMP3 is recycled back to the cell-surface24.
It is known that CLR•RAMP2 internalizes by a clathrin-dependent mechanism25. Once internalized 
CLR•RAMP2 colocalizes with the endosomal marker, transferrin and later is localized to acidic vesicles, pre-
sumably lysosomes25. However, it is not known if the duration of stimulus affects receptor fate as it does for 
CLR•RAMP114. The forward trafficking of CLR•RAMP2 to the cell-surface is connected to the C-terminal tail of 
RAMP2, as its deletion results in sequestration of CLR•RAMP2 in the endoplasmic reticulum26.
Figure 1. AM induces ubiquitination of CLR but not RAMP2. (A,B,D) HEK-CLR•RAMP2 or HMEC-
1-CLR•RAMP2 cells were not treated (NT) or incubated with AM (100 nM, 0–60 min). CLR was 
immunoprecipitated (IP) using an antibody to CLR (RK11, HEK; rat-HA, HMEC-1) and RAMP2 was 
immunoprecipitated using an antibody to the extracellular epitope tag of RAMP2 (rabbit-Myc, rMyc). 
Immunoprecipitates were analyzed by Western blotting (WB) and probed using antibodies to ubiquitin and 
the extracellular epitope tags of CLR (rabbit-HA, rHA) and RAMP2 (rMyc). (A) In HEK-CLR•RAMP2 cells 
there were low levels of ubiquitinated CLR and AM induced further ubiquitination of CLR at 60 min. (B) AM 
did not induce ubiquitination of RAMP2. There were no signals for CLR and RAMP2 in vector control cells, 
confirming specificity of immunoprecipitating antibodies and detection. (C) Quantification of ubiquitinated 
CLR in HEK cells. (D) In HMEC-1-CLR•RAMP2 cells there were low levels of ubiquitinated CLR, which were 
increased at 60 min by challenge with AM (100 nM) (E) Quantification of ubiquitinated CLR in HMEC-1 cells. 
n = 4. ANOVA and Student-Newman-Keuls post-hoc test, *p < 0.05; HEK-vc = HEK-vector control; HMEC-
1-vc = HMEC-1-vector control.
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Figure 2. AM does not induce ubiquitination of functionally active CLRΔ9KR (A,B) HEK-
CLRΔ9KR•RAMP2 or HMEC-1-CLRΔ9KR•RAMP2 cells were untreated or incubated with AM (100 nM, 
0-60 min). CLRΔ9KR was immunoprecipitated (IP) using an antibody to CLR (HEK, RK11; HMEC-1, ratHA). 
Immunoprecipitates were analyzed by Western blotting (WB) and probed using antibodies to ubiquitin and 
CLR (HEK, rabbit-HA, rHA; HMEC-1, mouse-HA, mHA). AM did not induce ubiquitination of CLRΔ9KR, 
whereas CLRΔ9KR was readily detected by the HA antibody. There were no signals in vector control cells, 
confirming specificity of antibodies. n = 3–4; HEK-vc = HEK-vector control. (C) Serum-starved HEK-
CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were not treated (NT) or incubated with AM (100 nM, 
0-10 min), washed and incubated in AM-free medium (0-120 min). Lysates were then analyzed for levels of 
phosphorylated (p) ERK2 (pERK2) and ERK2 by Western blotting. In untreated cells, levels of pERK2 were 
similarly low in both HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells. AM-induced a prompt increase 
in levels of pERK2 and returned towards basal levels after removal of agonist. The magnitude and duration of 
www.nature.com/scientificreports/
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The ubiquitination of eukaryotic GPCRs can function to facilitate internalization27, target the GPCR to lyso-
somes28–30 or regulate GPCR trafficking through the endocytic network and hence their rate of their proteolytic 
destruction31,32. In this study we aimed to determine if transient stimulation with AM promotes CLR•RAMP2 
recycling and the molecular mechanism regulating the post-endocytic sorting of CLR•RAMP2.
Results
AM Induces ubiquitination of CLR, but not RAMP2. It has previously been reported that CLR•RAMP2 
traffics to acidic vesicles following stimulation with AM, however the molecular mechanism regulating this traf-
ficking is unknown25. Attachment of ubiquitin moieties to lysine residues is required for the targeting of some, 
but not all GPCRs to lysosomes28–30,33. To determine whether AM caused ubiquitination of CLR or RAMP2, we 
incubated HEK-CLR•RAMP2 cells with AM, immunoprecipitated CLR and RAMP2 and probed Western blots 
for CLR, RAMP2 and ubiquitin. At all time points both CLR and RAMP2 were readily detected, with no sig-
nals present in cells not expressing receptor components (Fig. 1A,B). No signals for ubiquitinated RAMP2 were 
detected (Fig. 1B). However, ubiquitinated CLR could readily be detected 60 min post-stimulation (Fig. 1A,C).
As AM plays an important role in the maintenance of the endothelial cell barrier7, we investigated whether 
AM also induces ubiquitination of CLR when expressed in microvascular endothelial cells. HMEC-1 cells natu-
rally express functional CLR•RAMP2 but to facilitate biochemical studies, we virally transduced HMEC-1 cells 
with CLR and RAMP2 (Supplementary Fig. 1A–D). HMEC-1-CLR•RAMP2 cells were challenged with AM 
(0-60 min), CLR immunoprecipitated and Western blots probed for CLR and ubiquitin. CLR was readily detected, 
with no signals present in cells not expressing receptor components, indicating antibody specificity (Fig. 1D). 
AM induced ubiquitination of CLR after 60 min (Fig. 1D,E). Thus, sustained activation of CLR•RAMP2 with AM 
causes ubiquitination of CLR in HEK and HMEC-1 cells.
Mutation of the intracellular lysines of CLR does not affect CLR•RAMP2 expression and inter-
nalization. As ubiquitin molecules are mainly attached to lysine residues of target proteins34,35, we mutated all 
predicted intracellular lysine residues of CLR to arginine and examined the expression, trafficking, ubiquitination 
and mitogenic signaling of CLRΔ9KR•RAMP2. First, we determined if mutation of the lysine residues affected 
expression of the receptor. We expressed CLRΔ9KR•RAMP2 in HEK cells and compared the expression with the 
wild-type receptor (CLR•RAMP2). An antibody to the extracellular epitope (HA) of CLR recognized single pro-
teins of approximately the same size (~85 kDa) in both HEK-CLR•RAMP2 and HEK- CLRΔ9KR•RAMP2 cells 
(Supplementary Fig. 2A,B). The predicted molecular mass of CLR is 54 kDa, although there are six sites for poten-
tial N-linked glycosylation, which probably accounts for the larger apparent mass. An antibody to the extracellu-
lar epitope (Myc) of RAMP2 recognized two proteins in both HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 
cells with approximate molecular masses of 32 kDa and 37 kDa (Supplementary Fig. 2A,B). The predicted molec-
ular mass of RAMP2 is 19 kDa, thus we predict that the observed immunoreactive proteins represent ungly-
cosylated and glycosylated dimers of RAMP2, respectively. No signals were detected in HEK-vc cells, except 
for β-actin, which acted as a loading control, indicating specificity of detection (Supplementary Fig. 2A,B). A 
requirement for a functional receptor is expression at the cell-surface. To determine if mutation of lysine residues 
affected cell-surface expression we simultaneously localized CLR or CLRΔ9KR and RAMP2 using antibodies to 
the extracellular epitope tags of the receptor components. In unstimulated cells, CLR, CLRΔ9KR and RAMP2 
were present at the cell-surface. AM similarly induced trafficking of CLR with RAMP2 and CLRΔ9KR with 
RAMP2 to the same intracellular vesicles (Supplementary Fig. 2C,D). Together these data suggest that mutation 
of the intracellular facing lysine residues has no effect on the expression and internalization of CLR•RAMP2.
Mutation of the intracellular lysines of CLR prevents ubiquitination of CLR. Next we determined 
if mutation of the intracellular lysines residues affects ubiquitination of CLR. HEK- CLRΔ9KR•RAMP2 cells 
were stimulated with AM (0–60 min), CLR immunoprecipitated and Western blots probed for ubiquitin and 
CLRΔ9KR. In contrast, to CLR (Fig. 1A), no ubiquitination of CLRΔ9KR could be detected (Fig. 2A). We per-
formed a similar experiment in HMEC-1 cells expressing CLRΔ9KR and similarly did not detect ubiquitination 
of CLRΔ9KR (Fig. 2B). Thus, the intracellular lysine residues are required for AM-induced ubiquitination of 
CLR.
Ubiquitination has no effect on AM-induced ERK Activation. Ubiquitination of receptors and associ-
ated proteins has been shown to influence the signaling properties of activated receptors36–38, therefore we exam-
ined if ubiquitination of CLR regulates AM-induced ERK1/2 activation. Serum-starved HEK-CLR•RAMP2 and 
HEK-CLRΔ9KR•RAMP2 cells were incubated with AM (10 min), incubated in AM-free medium (0–110 min) 
and phosphorylated (p) and total ERK2 analyzed by Western blotting. In untreated cells, levels of pERK2 were low 
(Fig. 2C,D). In HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells, AM induced phosphorylation of ERK2 
that peaked at 10 minutes and before returning back to basal. Lack of CLR ubiquitination had no effect on the 
magnitude of the initial and sustained activation of ERK2 (Fig. 2C,D; Supplementary Fig. 3). Thus, we conclude 
that ubiquitination of CLR has no role in the generation of AM-induced ERK signaling.
ERK2 activation is unaffected by the ubiquitination of CLR. (D) Quantification of levels of pERK1/2 in HEK-
CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells. Results are expressed as % of maximal response (10 min, 
100%). n = 3. Full length blots of panel B are shown in Supplementary Fig. 3.
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Ubiquitination of CLR does not affect trafficking of CLR•RAMP2. Ubiquitination of certain 
GPCRs is required for lysosomal targeting and degradation28–30, therefore determined ubiquitination of CLR 
affects trafficking. First, we determined if CLRΔ9KR traffics to early endosomes, similar to that reported for the 
wild-type receptor25. HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were incubated with AM (30 min) 
and CLR and a marker for early endosomes, early endosomal antigen-1 (EEA1) localized by immunofluores-
cence and confocal microscopy. In unstimulated cells, both CLR and CLRΔ9KR were present at the cell-surface 
and EEA1 was present in intracellular vesicles (Fig. 3A,B). AM similarly induced trafficking of both CLR and 
CLRΔ9KR from the cell-surface to colocalize with EEA1, indicating trafficking to early endosomes (Fig. 3A,B,E). 
We next determined if ubiquitination of CLR is required for lysosomal targeting. HEK-CLR•RAMP2 and 
HEK-CLRΔ9KR•RAMP2 cells were incubated with lysosomal peptidase inhibitors, incubated with AM for 4 h 
and CLR and LAMP1 (a marker for lysosomes) were localized. In unstimulated cells, CLR and CLRΔ9KR were 
present at the cell-surface and LAMP1 was detected in intracellular vesicles (Fig. 3C,D). Incubation with AM 
caused internalization of CLR and CLRΔ9KR to colocalize with LAMP1, indicating trafficking to lysosomes 
(Fig. 3C,D,F). Thus, ubiquitination of CLR is not required for the lysosomal targeting of CLR.
The duration of the AM challenge does not affect the trafficking or fate of activated CLR or 
CLRΔ9KR. It has previously been shown that the trafficking and fate of the CGRP receptor (CLR•RAMP1) is 
dependent on the duration of stimulation14. To determine whether the duration of stimulation with AM similarly 
affects the trafficking of CLR•RAMP2, we examined levels of CLR, CLRΔ9KR and RAMP2 following either con-
tinuous or transient stimulation with AM. To examine degradation of cell-surface CLR and RAMP2, we employed 
a cell-surface biotinylation assay. HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were challenged with 
AM (30 min), washed and incubated in AM-free medium for 16 h or alternatively, cells were incubated contin-
uously with AM (16 h), biotinylated proteins immunoprecipitated and levels of CLR, CLRΔ9KR, RAMP2 and 
transferrin receptor (loading control) determined by Western blotting. In untreated HEK-CLR•RAMP2 and 
HEK-CLRΔ9KR•RAMP2 cells, CLR, CLRΔ9KR and RAMP2 were readily detected (Fig. 4A–D, Supplementary 
Fig. 4A,B). In contrast, to CLR•RAMP1, which only recycles following transient stimulation14, both transient and 
continuous stimulation of CLR•RAMP2 with AM caused significant degradation of CLR, CLRΔ9KR and RAMP2 
(Fig. 4A–D, Supplementary Fig. 4A,B). As significantly less CLR, CLRΔ9KR and RAMP2 were degraded follow-
ing a transient stimulation compared to a sustained stimulation (Fig. 4E,F), we investigated whether this was due 
Figure 3. CLR and CLRΔ9KR traffic through the endocytic network to early endosomes and lysosomes. 
(A,B) HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were left unstimulated or challenged with 
AM (100 nM, 30 min), fixed, permeabilized and CLR and a marker for early endosomes (EEA1) localized 
by immunofluorescence and confocal microscopy. In unstimulated cells, CLR and CLRΔ9KR were present 
at the cell-surface (arrowheads) and EEA1 was detected in intracellular vesicles. AM induced trafficking of 
CLR and CLRΔ9KR to colocalize with EEA1 in early endosomes (arrows). (C,D) HEK-CLR•RAMP2 and 
HEK-CLRΔ9KR•RAMP2 cells were incubated with lysosomal protease inhibitors, challenged with vehicle 
(control) or AM (100 nM, 4 h), fixed, permeabilized and CLR and a marker for lysosomes (LAMP1) localized by 
immunofluorescence and confocal microscopy. In unstimulated cells, CLR and CLRΔ9KR were present at the 
cell-surface (arrowheads) and LAMP1 was detected in intracellular vesicles. AM induced trafficking of CLR and 
CLRΔ9KR to colocalize with LAMP1 in lysosomes (arrows). (E,F) Quantification of colocalization of CLR with 
EEA1 and LAMP1, respectively. n = 3, Scale bar, 10 µm.
www.nature.com/scientificreports/
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to receptor recycling or reduced loss of cell-surface receptors. To determine the loss of cell-surface CLR•RAMP2 
during the 30 minute time period we used flow cytometry. HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 
cells were labeled with antibodies to the extracellular epitope of RAMP2, washed, challenged with AM (30 min) 
and levels of receptor remaining on the cell-surface determined. In untreated cells, levels of CLR•RAMP2 and 
CLRΔ9KR•RAMP2 were similar (Supplementary Fig. 5A, left panel). AM (30 min) induced a significant reduc-
tion in cell-surface expression of both CLR•RAMP2 and CLRΔ9KR•RAMP2 (Supplementary Fig. 5A, right 
panel; 5B, C) which is remarkably consistent with the levels of degradation determined by cell-surface biotiny-
lation assay (Fig. 4E,F). We incubated cells for an additional period (1 h) after removal of AM and observed a 
further small increase in the internalization of CLR•RAMP2 and CLRΔ9KR•RAMP2 (Supplementary Fig. 5A, 
right panel). In a complimentary experiment, we localized CLR, CLRΔ9KR and LAMP1 by immunofluorescence 
Figure 4. AM induces degradation of CLR, CLRΔ9KR and RAMP2 following continuous and transient 
challenges. Cell-surface biotinylated HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were not treated 
(NT) or challenged with AM (100 nM, as indicated), biotinylated proteins immunoprecipitated (IP) and 
Western blots (WB) probed for CLR (rabbit-HA, rHA), CLRΔ9KR (rHA), RAMP2 (rMyc) and transferrin 
receptor (TfR, loading control). (A,B) In untreated HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 
cells, CLR, CLRΔ9KR, RAMP2 and TfR were readily detected. AM (100 nM, 16 h) induced degradation 
of CLR, CLRΔ9KR and RAMP2 to similar levels. (C,D) In untreated HEK-CLR•RAMP2 and HEK-
CLRΔ9KR•RAMP2 cells, CLR, CLRΔ9KR, RAMP2 and TfR were readily detected. AM (100 nM, 30 min, 
followed by 16 h incubation on AM-free medium) induced degradation of CLR, CLRΔ9KR and RAMP2 to 
similar levels. (E,F) Quantification of the degradation of CLR and CLRΔ9KR and RAMP2. n = 3–4. Data were 
compared by Student’s t test and differences among multiple groups were examined using ANOVA and Student-
Newman-Keuls post-hoc test, ***p < 0.001. Full length blots of panels A and C are shown in Supplementary 
Fig. 4.
www.nature.com/scientificreports/
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and confocal microscopy. HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were transiently stimulated 
with AM (30 min), AM removed and proteins localized after 4 h. Transient stimulation promoted the trafficking 
of both CLR and CLRΔ9KR to LAMP1-positive vesicles (Supplementary Fig. 6A,B). Thus, we conclude that 
once activated, CLR•RAMP2 is removed from the cell-surface, does not recycle to the cell-surface, traffics to 
LAMP1-positive vesicles and that CLR•RAMP2 and CLRΔ9KR•RAMP2 are lost from the cell-surface to similar 
degrees following a 30 min exposure to AM.
Lysosomal peptidases participate in the degradation of CLR•RAMP2 and CLRΔ9KR•RAMP2. 
Lysosomal and proteasomal peptidases have both been implicated in the degradation of GPCRs39,40. Therefore, we 
investigated the peptidases responsible for the degradation of CLR, CLRΔ9KR and RAMP2. HEK-CLR•RAMP2 
and HEK-CLRΔ9KR•RAMP2 cells were preincubated with lysosomal peptidase inhibitors or vehicle (control) 
and stimulated with AM. We then determined levels of CLR, CLRΔ9KR, RAMP2 and TfR by Western blotting. 
In vehicle-treated cells CLR, CLRΔ9KR and RAMP2 were degraded to similar levels (Fig. 5A–D). Incubation 
with lysosomal inhibitors partially prevented degradation of CLR, CLRΔ9KR and RAMP2 by similar amounts 
(Fig. 5A–D). Thus, lysosomal peptidases partially regulate the degradative process, irrespective of whether CLR 
is ubiquitinated or not.
To further determine if lysosomal peptidases are involved in the degradation of CLR and RAMP2, 
we determined the effect of the serine protease inhibitor, leupeptin an inhibitor that has been used to 
prevent the degradation of other GPCRs41. HEK-CLR•RAMP2 cells were treated as above and deg-
radation of CLR, RAMP2 and TfR determined by Western blotting. Incubation of cells with leupep-
tin did not prevent the degradation of CLR and RAMP2 (Supplementary Fig.  7A–C). Although the 
degradation of GPCRs by the proteasome is unusual39,40, we investigated the role of the proteasome in 
the degradation of CLR•RAMP2. We quantified degradation of CLR, CLRΔ9KR and RAMP2 in the 
presence of the highly specific proteasome inhibitor, epoxomicin. In vehicle- and epoxomicin-treated 
cells, CLR, CLRΔ9KR and RAMP2 were degraded to similar levels (Supplementary Fig.  8A–D). 
Thus, the proteasome plays no role in the degradation of CLR, CLRΔ9KR and RAMP2.
Kinetics of degradation of CLR•RAMP2 are not regulated by AM-induced ubiquitination. 
Ubiquitination of GPCRs has also been shown to regulate the degradation rate by altering the trafficking through 
the endocytic system (25,26). Therefore we determined if ubiquitination altered the rate of degradation of CLR, 
CLRΔ9KR and RAMP2 by examining degradation following stimulation with AM at a shorter time points. 
HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were stimulated with AM (0–4 h) and we then deter-
mined levels of CLR, CLRΔ9KR, RAMP2 and TfR. In HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells, 
CLR, CLRΔ9KR and RAMP2 were degraded to similar levels (Fig. 6A–D). We also performed the same experi-
ments in HMEC-1 cells and observed similar results (Supplementary Fig. 9A–C). Thus, AM-induced ubiquitina-
tion of CLR does not affect the kinetics of degradation.
HRS regulates the degradation of ubiquitinated CLR•RAMP2, but not CLRΔ9KR•RAMP2. HRS 
is an endosomal sorting protein that has previously been shown to play a role in the trafficking and degradation of 
CLR•RAMP119. Therefore we investigated if HRS also regulates the degradation of CLR•RAMP2. We quantified the 
overexpression of HRS in HEK cells expressing HRS and either CLR•RAMP2 or CLRΔ9KR•RAMP2 (Fig. 7A,B). 
The same cells were incubated with AM (0–4 h) and levels of CLR, CLRΔ9KR and RAMP2 determined. Expression 
of HRS prevented the degradation of both CLR and RAMP2 in cells expressing CLR•RAMP2 (Fig. 7C–F). In con-
trast, expression of HRS did not affect the degradation of CLRΔ9KR and RAMP2 in CLRΔ9KR•RAMP2 cells 
(Fig. 7C–F). Thus, HRS is not required for the degradation of CLRΔ9KR.
Ubiquitin-interaction motif of HRS does not regulate degradation of ubiquitinated CLR. HRS 
concentrates ubiquitinated receptors by direct interaction with its ubiquitin-interaction motif (UIM)42. Therefore 
we investigated if the UIM of HRS was essential for its regulation of CLR degradation. Overexpression of 
HRSΔUIM in HEK cells expressing HRS and either CLR•RAMP2 or CLRΔ9KR•RAMP2 was quantified by 
Western blotting (Supplementary Fig. 8A,B). The same cells were incubated with AM (0–4 h) and levels of CLR, 
CLRΔ9KR and RAMP2 quantified (Supplementary Fig. 10C–F). In HEK cells expressing HRSΔUIM and either 
CLR•RAMP2 or CLRΔ9KR•RAMP2 cells, we observed similar degradation profiles for CLR, CLRΔ9KR and 
RAMP2 as when they are co-expressed with HRS (Supplementary Fig. 10C–F). Thus, the UIM of HRS is not 
involved in the HRS-dependent regulation of CLR degradation.
Knockdown of HRS does not affect AM-induced degradation of CLR•RAMP2. To further exam-
ine the role of HRS in the degradation of CLR•RAMP2, we used two separate siRNAs to knockdown expression 
of HRS. Quantification of HRS knockdown was determined by Western blotting (Fig. 8A,B). HEK cells tran-
siently expressing CLR•RAMP2 that had been treated with transfection reagent alone (Mock), non-targeting 
pool of siRNA (Scr) or two single siRNAs against HRS were exposed to AM (0–4 h) and degradation of CLR 
and RAMP2 examined by Western blotting. In Mock and Scr cells, both CLR and RAMP2 were degraded 
(Fig. 8A,C,D, Supplementary Fig. 11A,B). Surprisingly, knockdown of HRS had no effect of the degradation of 
CLR and RAMP2 (Fig. 8A,C,D).
CLR•RAMP2 constitutively traffics to HRS-positive vesicles. HRS regulates the ubiqutination and 
deubiquitination of the epidermal growth factor receptor21. We hypothesized that HRS may also regulate the 
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Figure 5. Inhibition of lysosomal peptidases partially prevents degradation of CLR•RAMP2 and 
CLRΔ9KR•RAMP2. (A, C) Cell-surface biotinylated HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 
cells were incubated with vehicle (control), lysosomal peptidase inhibitors (LI), not treated (NT) or challenged 
with AM (100 nM, 16 h), biotinylated proteins immunoprecipitated (IP) and Western blots (WB) probed for 
CLR (rabbit-HA, rHA), CLRΔ9KR (rHA), RAMP2 (rabbit-Myc, rMyc) and transferrin receptor (TfR, loading 
control). In untreated HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells, CLR, CLRΔ9KR, RAMP2 and 
TfR were readily detected. AM (100 nM, 16 h) induced degradation of CLR, CLRΔ9KR and RAMP2 to similar 
levels. (B) Quantification of the degradation of CLR and CLRΔ9KR, respectively. (D) Quantification of the 
degradation of RAMP2. n = 4, Data were compared by Student’s t test, *p < 0.05, HEK-vc = HEK-vector control.
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degradation of CLR•RAMP2 by regulating the basal ubiquitination pattern of CLR. As a first step, we investigated 
if CLR•RAMP2 constitutively trafficked to HRS-positive vesicles. An antibody to the N-terminal epitope tag of 
RAMP2 was added to HEK cells expressing CLR•RAMP2 and cells immediately fixed or incubated for 2 h to 
allow constitutive trafficking to occur. We observed that CLR•RAMP2 constitutively internalizes and traffics to 
HRS-positive vesicles, presumably endosomes (Fig. 9A). Next, we determined the effect of HRS overexpression on 
the basal localization of CLR•RAMP2. In HEK-CLR•RAMP2 cells expressing empty vector (control), CLR was 
present at the cell-surface and HRS was present in intracellular vesicles (Fig. 9B). However, in HEK-CLR•RAMP2 
cells overexpressing HRS, CLR was present at both the cell-surface and in HRS-positive intracellular vesicles 
(Fig. 9B). We also investigated the effect of HRS knockdown on the localization of CLR•RAMP2. We observed 
that for both siRNAs, CLR was present at the cell-surface, similar to that observed in Mock and Scr cells (Fig. 9C).
HRS regulates the basal ubiquitination of CLR. As CLR was observed to co-localize with both endog-
enous and overexpressed HRS, we determined the effect of overexpressing and knockdown of HRS on the basal 
ubiquitination levels of CLR using immunoprecipitation and Western blotting. Quantification of HRS expression 
in each experimental condition was determined by Western blotting (Fig. 9D,E). In the control cells (empty 
vector, Mock, Scr) a comparable level of basal CLR ubiquitination could be detected (Fig. 9D,F). Similar basal 
levels of ubiquitination were also detected in cells lacking HRS (Fig. 9D,F). In contrast, basal CLR ubiquitina-
tion was significantly enhanced in cells overexpressing HRS (Fig. 9D,F). Therefore, CLR constitutively traffics to 
HRS-positive vesicles and HRS regulates the basal level of CLR ubiquitination.
CLR•RAMP2 and CLRΔ9KR•RAMP2 traffic to HRS- and LAMP1-positive vesicles in HRS over-
expressing cells. Next we determined the effect of increased HRS expression on AM-induced trafficking of 
CLR and CLRΔ9KR. We overexpressed HRS, live labeled CLR at the cell-surface and used immunofluorescence 
and confocal microscopy to localize CLR, CLRΔ9KR, HRS and LAMP1 following treatment with AM (0–4 h). 
In unstimulated HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells, CLR was present at the cell-surface, 
HRS in enlarged endosomes and LAMP1 intracellular vesicles (Fig. 10A,B). Following stimulation with AM, 
CLR and CLRΔ9KR similarly trafficked to enlarged HRS-positive vesicles (Fig. 10A–C). However, both CLR and 
CLRΔ9KR could also be similarly detected in LAMP1-positive vesicles (Fig. 10A,C,D). Of note, we could also 
detect LAMP1 in HRS-positive vesicles (Supplementary Fig. S12A,B).
Figure 6. Early kinetics of CLR, CLRΔ9KR and RAMP2 degradation. (A,B) Cell-surface biotinylated HEK-
CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells were not treated (NT) or challenged with AM (100 nM, 
2-4 h), biotinylated proteins immunoprecipitated (IP) and Western blots (WB) probed for CLR (mouse-HA, 
mHA), CLRΔ9KR (mHA), RAMP2 (mouse-Myc, mMyc) and transferrin receptor (TfR, loading control). In 
untreated HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells, CLR, CLRΔ9KR, RAMP2 and TfR were 
readily detected. AM (100 nM, 4 h) induced degradation of CLR, CLRΔ9KR and RAMP2 to similar levels. 
(C,D) Quantification of the degradation of CLR, CLRΔ9KR and RAMP2. n ≥ 4. Data were examined using 
ANOVA and Student-Newman-Keuls post-hoc test, *p < 0.05, **p < 0.01, ***p < 0.001.
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Enhanced basal ubiquitination of CLR delays degradation of CLR•RAMP2. To investigate if over-
expression of HRS simply ‘traps’ ubiquitinated CLR•RAMP2 in HRS-positive vesicles, we analyzed the degra-
dation of CLR and RAMP2 following long-term exposure to AM (16 h). We first quantified expression of HRS 
in HEK cells expressing empty vector (control) or HRS and CLR•RAMP2 by Western blotting (Fig. 11A,B). We 
then treated the same cells with AM (0–16 h) and levels of CLR, RAMP2 and TfR quantified by Western blotting 
(Fig. 11A,C,D). In control cells, AM induced significant degradation of both CLR and RAMP2 compared to the 
not treated control and AM-treated cells overexpressing HRS. In contrast, AM induced significant degradation of 
RAMP2, but not CLR in cells overexpressing HRS (Fig. 11A,C,D). Thus, overexpression of HRS does not prevent, 
but only impedes the degradation of CLR•RAMP2.
Discussion
In this study, we used HEK cells to detail the molecular mechanisms regulating the downregulation of the AM1 
receptor. Our results show that AM induces trafficking of CLR•RAMP2 to early endosomes and then onto lyso-
somes. Furthermore, CLR is trafficked to lysosomes following both transient and sustained stimulation with AM. 
We also show that AM induces ubiquitination of CLR on intracellular lysines residues and that although ubiquitin 
does not target CLR•RAMP2 for degradation, a basal hyperubiquitination mediated by HRS overexpression does 
prevent degradation.
Ubiquitination has been shown to play a major role in the regulation of many GPCRs (reviewed in refs43,44). 
However, ubiquitination of CLR expressed with RAMP2 was unexpected, given that CGRP does not induce 
ubiquitination of CLR when expressed with RAMP114. The kinetics of agonist-induced CLR ubiquitination was 
unexpected. Most previously reported agonist-induced ubiquitination of GPCRs occurs within minutes28,30. 
However, we only detected ubiquitinated CLR, 1 h post-stimulation. To our knowledge, the only other GPCR 
that undergoes delayed ubiquitination is the neurokinin 1 receptor. However, these studies were performed in a 
cell line that does not naturally express that receptor45. Our finding that AM induced ubiquitination of CLR in an 
epithelial (HEK) and endothelial cell (HMEC-1) suggests that this may be a universal mechanism that regulates 
AM1 receptors.
We generated a mutant CLR lacking all intracellular facing lysine residues to study the role of CLR ubiquit-
ination. We observed that AM did not induce ubiquitination of CLRΔ9KR, but this lack of ubiquitination did 
not affect the endocytic trafficking to lysosomes. This finding was not unexpected as although ubiquitination 
does affect the trafficking of some GPCRs28,30, it does not regulate the lysosomal targeting of others14,31,33. We also 
observed a basal level of CLR ubiquitination, indicating that perhaps CLR is constitutively ubiquitinated. Again, 
this is not unusual as PAR1 is constitutively ubiquitinated in order to prevent its internalization46.
Figure 7. Effect of HRS on the degradation of CLR, CLRΔ9KR and RAMP2. (A,B) Cell lysates from 
experimental cells were analyzed by Western blotting and levels of HRS and β-actin quantified. (C,D) Cell-
surface biotinylated HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells expressing HRS were not treated 
(NT) or challenged with AM (100 nM, 2-4 h), biotinylated proteins immunoprecipitated (IP) and Western blots 
(WB) probed for CLR (mouse-HA, mHA), CLRΔ9KR (mHA), RAMP2 (mouse-Myc, mMyc) and transferrin 
receptor (TfR, loading control). In untreated HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells, CLR, 
CLRΔ9KR, RAMP2 and TfR were readily detected. AM (100 nM, 4 h) induced degradation of CLR, CLRΔ9KR 
and RAMP2 to different levels. (E,F) Quantification of degradation of CLR, CLRΔ9KR and RAMP2. n = 4, 
Data were examined using ANOVA and Student-Newman-Keuls post-hoc test, *p < 0.05, **p < 0.01, 
***p < 0.001.
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The duration of agonist exposure in known to influence ultimate fate of GPCRs. Transient exposure of 
CLR•RAMP1 to CGRP results in efficient recycling14,15. However, continued CGRP exposure promotes traf-
ficking to lysosomes14. The trafficking of the neurokinin 1 receptor can be similarly modified45,47. CLR•RAMP3, 
the other receptor for AM, has been shown to internalise and recycle back to the cell-surface following agonist 
exposure24. Our results indicate that once activated CLR•RAMP2 is degraded. This was unexpected as we had 
expected CLR•RAMP2 to be similarly regulated by endothelin-converting enzyme 1, especially as this endosomal 
peptidase cleaves AM in a pH-dependent manner, similar to that observed with CGRP (Cottrell, unpublished 
observation). However, the lack of CLR•RAMP2 recycling is in agreement with a previous study where it has 
been reported that following a transient stimulation with AM (30 min), CLR•RAMP2 is internalised and less than 
10% of CLR•RAMP2 recycles back to cell-surface after 2 h25. Thus, it appears that in addition to modifying the 
pharmacology of CLR13, RAMPs play an important role in the post-endocytic sorting of CLR following agonist 
stimulation and can change the fate of CLR•RAMP complex.
As CLR colocalized with the lysosomal marker LAMP-1, we expected that degradation of CLR•RAMP2 
would be prevented by inhibitors of lysosomal peptidases. However, the lysosomal protease inhibitors cocktail 
that completely prevented CGRP-induced degradation of CLR•RAMP114, did not affect AM-induced degrada-
tion of CLR•RAMP2. Furthermore, leupeptin that has been shown to prevent degradation of other GPCRs41, 
did not prevent degradation of the AM1 receptor. This result suggests that GPCRs may be degraded by different 
repertoires of peptidases. Studies have shown that δ-opioid receptor (δ-OR) degradation is prevented by MG-132, 
which is often used to inhibit the proteolytic activity of the proteasome33,39. However, MG-132 has been found to 
inhibit certain cathepsins e.g. B, L and K found in lysosomes48–50. Our data using the highly specific proteasome 
inhibitor, epoxomicin, suggests the proteasome has no role in the degradation of CLR•RAMP2.
Ubiquitin-dependent alterations in mitogenic signaling have been observed for other cell-surface recep-
tors36,38. Ubiquitination of insulin-like growth factor 1 receptor is an absolute requirement for insulin-like growth 
factor-induced ERK activation36. We were unable to detect any changes in AM-induced mitogenic signaling, but 
that does not rule out the fact that other AM-induced signaling cascades may be altered.
Figure 8. Effect of HRS knockdown on degradation of CLR, CLRΔ9KR and RAMP2. (A,B) Cell-surface 
biotinylated HEK cells expressing CLR•RAMP2 or CLRΔ9KR•RAMP2 and either mock transfected (Mock, 
control) or transfected with a non-targeting pool of siRNA (Scr) or siRNA to HRS (siRNA #1 and #2) were 
not treated (NT) or challenged with AM (100 nM, 4 h), biotinylated proteins immunoprecipitated (IP) and 
Western blots (WB) probed for CLR (mouse-HA, mHA), CLRΔ9KR (mHA), RAMP2 (mouse-Myc, mMyc) and 
transferrin receptor (TfR, loading control). In untreated HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 
cells, CLR, CLRΔ9KR, RAMP2 and TfR were readily detected in all treatment types. AM (100 nM, 4 h) induced 
significant degradation of CLR, CLRΔ9KR and RAMP2 to similar levels in each cell type. (C) Quantification 
of the knockdown of HRS by siRNA. (D,E) Quantification of the degradation of CLR, CLRΔ9KR and RAMP2. 
n ≥ 4, Data were compared by Student’s t test, *p < 0.05, **p < 0.01, ***p < 0.001. Full length blots of panels A 
and C are shown in Supplementary Fig. 9.
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Ubiquitination has been shown to participate in many different phases of GPCR regulation, such as promot-
ing27 or preventing internalisation46, targeting to lysosomes for degradation28,30 and increasing the rate of deg-
radation31. We examined if AM promoted degradation of CLR•RAMP2 and CLRΔ9KR•RAMP2 with different 
kinetics by examining degradation at early time points. However, we did not observe any significant differences 
in the degradation of CLR, CLRΔ9KR or RAMP2 in HEK cells or HMEC-1 cells. This finding was unexpected 
as ubiquitination usually either regulates internalization, lysosomal targeting or degradation kinetics27,28,30,31,46.
HRS overexpression regulates the degradation of the δ-OR20, protease-activated receptor 2, the CGRP recep-
tor (CLR•RAMP1)19 and the recycling of the β2-adrenoceptor18. The pronounced difference in the sensitivity of 
CLR•RAMP2 and CLRΔ9KR•RAMP2 to HRS overexpression indicates that ubiquitination plays a key role in 
the movement of AM1 receptors through the endocytic machinery. However, as the lysine defective mutant is 
still degraded, an alternative pathway must be open to the receptor if it is not ubiquitinated. One possibility is 
that it could follow a similar pathway to PAR1 which has been shown to be degraded in lysosomes in an HRS- 
and ubiquitin-independent but ESCRT-III-dependent mechanism51,52, although both CLR and RAMP2 lacks the 
Figure 9. Colocalization of CLR and RAMP2 with HRS and effect of HRS expression on the basal levels of CLR 
ubiqutination. (A) HEK cells expressing CLR•RAMP2 were live labeled with an antibody to the extracellular 
epitope tag of RAMP2 (rabbit-Myc, rMyc) and fixed (control) or left for 2 h at 37 °C (2 h Recovery) before 
fixation. RAMP2 and HRS were localized using immunofluorescence. In control cells, RAMP2 was detected 
at the cell-surface (arrowheads). Following 2 h incubation, RAMP2 was also at the cell-surface (arrowheads), 
but could be detected in intracellular HRS-positive vesicles. (B) HEK cells expressing CLR•RAMP2 and 
empty vector (pcDNA3, control) or Myc-HRS were fixed permeablized and CLR (RK11) and HRS localized 
using immunofluorescence and confocal microscopy. In control cells CLR was detected at the cell-surface 
(arrowheads). In cells overexpressing HRS-myc, CLR was detected at the cell-surface, but also in enlarged 
HRS-positive endosomes. (C) HEK cells expressing CLR•RAMP2 and either mock transfected (control) or 
transfected a non-targeting pool siRNA (Scrambled) or siRNA to HRS (siRNA #1 and #2) were fixed and CLR 
and HRS localized by immunofluorescence and confocal microscopy. In all conditions CLR was detected at 
the cell-surface and HRS was detected in intracellular vesicles, with the exception of siRNA#1- and #2-treated 
cells were limited detection of HRS was possible due to knockdown. n = 3. Scale bar, 10 µm. (D) HEK cells 
expressing CLR•RAMP2 and either empty vector (pcDNA3, control, +vc), Myc-HRS, mock transfected (Mock, 
control) or transfected with a non-targeting pool siRNA (Scr) or siRNA to HRS (siRNA #1 and #2) were lysed, 
CLR immunoprecipitated (mouse HA, mHA) and Western blots probed using antibodies to ubiquitin and CLR 
(mHA). There were no signals for CLR in vector control cells, confirming antibody specificity. In Scr, siRNA#1 
and siRNA#2 cells the basal levels of ubiquitination were similar to control (Mock). In contrast, in cells 
overexpressing HRS, the basal level of ubiquitinated CLR was significantly increased over control (+vc). (E) 
Quantification of HRS expression. (F) Quantification of ubiquitinated CLR. Data were examined using ANOVA 
and Student-Newman-Keuls post-hoc test, n = 4. *p < 0.05; **p < 0.01; ***p < 0.001. HEK-vc = HEK-vector 
control.
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YPX(3)L motif necessary for the interaction with ALIX (an ESCRT-III–interacting protein). However, this still 
reinforces the idea that similar to the protease-activated receptors the AM1 receptor is a one-shot receptor because 
irrespective of whether the receptor is ubiquitinated or not, it is destined for degradation. Deletion of the UIM of 
HRS did not rescue CLR•RAMP2 degradation indicating HRS is not the endosomal sorting protein responsible 
for the recognition of ubiquitinated CLR. Numerous endosomal sorting proteins contain UIMs including EPS15, 
epsins, the ESCRT-0 component, STAM, the ESCRT-I component TSG101, the ESCRT-II component VPS36, as 
well as EPS15b and GGA3 (reviewed in ref.53). Thus, it is plausible that anyone of these proteins is responsible for 
the recognition and sorting of ubiquitinated AM1 receptors.
Considering that degradation of other GPCRs and their lysine-deficient mutants is inhibited by HRS knock-
down19,20, it was surprising that knockdown of HRS had no effect on AM-induced degradation of CLR•RAMP2 
or CLRΔ9KR•RAMP2. Furthermore, CLR•RAMP2 also localized to enlarged HRS-positive vesicles following 
HRS overexpression, similar to protease-activated receptor 2, CLR•RAMP1 and δ-OR19,20. Investigation into the 
effect of HRS overexpression on AM-induced trafficking revealed that both CLR and CLRΔ9KR accumulate in 
HRS- and LAMP1-positive vesicles, although it was clear that both receptors predominantly colocalized with 
HRS. It was surprising that there was no difference in the colocalization of CLR and CLRΔ9KR with LAMP1 and 
that the colocalization of CLRΔ9KR with LAMP1 was far less than in the absence of HRS overexpression given 
the HRS overexpression did not affect AM-induced degradation of CLRΔ9KR. It should also be noted that we 
used antibody-tagged receptors in our immunofluorescence experiments (to circumvent the high level of CLR 
colocalization with HRS under basal conditions) and so we visualized the antibodies used for tagging and not 
the receptors themselves. Therefore, we cannot rule out that the antibodies using for tagging the receptors are 
degraded at similar rates, whereas the receptors themselves are not. Furthermore, in our biochemical experi-
ments, we cannot rule out pre-lysosomal proteolysis of the epitope tag used to detect both CLR and CLRΔ9KR.
Unlike other receptors that have been shown to be regulated by HRS overexpression it is clear from our results 
that HRS overexpression does not prevent degradation of CLR•RAMP2, but only delays degradation. Thus, it is 
possible that degradation of other GPCRs such as the δ-OR20 and PAR219 is only retarded, as in those investiga-
tions longer time points (>4 h) were not investigated.
Our discovery that CLR•RAMP2 constitutively traffics to HRS-positive endosomes and HRS overexpres-
sion promotes hyperubiquitination of CLR under basal conditions could provide an explanation for the differ-
ences observed in the degradation of CLR•RAMP2 and CLRΔ9KR•RAMP2 (Fig. 12). If HRS recruits an E3 
Figure 10. CLR•RAMP2 and CLRΔ9KR•RAMP2 traffic to HRS- and LAMP1-positive vesicles in HRS 
overexpressing cells. (A,B) In HEK-CLR•RAMP2 and HEK-CLRΔ9KR•RAMP2 cells overexpressing 
HRS, cell-surface CLR and CLRΔ9KR were labelled using an antibody to the epitope tag (goat-HA, gHA) 
were challenged with AM (100 nM, 0–4 h), fixed, permeabilized and CLR, CLRΔ9KR, HRS and a marker 
for lysosomes (LAMP1) localized by immunofluorescence and confocal microscopy. In unstimulated cells 
(top panels), CLR and CLRΔ9KR were present at the cell-surface (arrowheads) and LAMP1 was detected in 
intracellular vesicles (white arrows) and HRS in enlarged intracellular vesicles (white arrows). AM induced 
similar trafficking of CLR and CLRΔ9KR to colocalize with HRS (lower panels white arrows) and LAMP1 in 
lysosomes (blue arrows). (C,D) Quantification of CLR and CLRΔ9KR colocalization with HRS and LAMP1. 
n = 3. Data were examined using ANOVA and Student-Newman-Keuls post-hoc test. Scale bar, 10 µm.
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ligase, such as UBE4B21 that ubiquitinates CLR, then the hyperubiquitination that occurs during the constitutive 
trafficking of CLR•RAMP2 could perturb the endocytic transport of CLR•RAMP2 to the lysosome following 
activation. A similar effect on the ubiquitination state and degradation of PAR2 is observed following overexpres-
sion of a dominant-negative mutant of the deubiquitinating enzyme, associated molecule with the SH3 domain 
of STAM (AMSH)54. In contrast, trafficking of non-ubiquitinated CLRΔ9KR•RAMP2 is compromised by dis-
ruption of the endocytic network by HRS overexpression, but degradation can still occur by incorporation of 
LAMP1-positive vesicles into the MVB. HRS knockdown on the other hand, would not result in increased ubiq-
uitination and wild-type receptors would either traffic as normal or via the route of non-ubiquitinated mutant 
CLRΔ9KR•RAMP2. Our data shows that basal ubiquitination of CLR•RAMP2 can be regulated by HRS expres-
sion and that basal ubiquitination levels regulate agonist-induced degradation.
Methods
Reagents. Sources of antibodies were: rabbit anti-rat CLR (RK11) was a gift from Nigel W. Bunnett (Monash 
University, Victoria, Australia)55); mouse anti-pERK (E-4, raised to Tyr204, Lot No. L1311), rabbit anti-ERK2 
(C-14, Lot No. A1509), mouse anti-ubiquitin (P4D1, Lot No. G0609), mouse anti-lysosomal-associated gly-
comembrane protein 1 (LAMP1, H4A3, Lot No. G0109, Insight Biotechnology, Wembley, UK); mouse anti-early 
endosomal antigen-1 (EEA1, BD Transduction Laboratories, Oxford, UK, Lot No. 52897); mouse anti-hu-
man transferrin receptor (Lot No. 136800), donkey anti-mouse or rabbit IgG coupled to AlexaFluor488 or 546 
(Invitrogen, Paisley, UK); rabbit anti-HA (H6908, Lot No. 118K4800), mouse anti-β-actin (A5441, Lot No. 
028K4826), rabbit anti-c-Myc (C3956, Lot No. 098K4806); mouse anti-c-Myc (clone 9E10, M4439, Lot No.) 
121M4826; mouse anti-HRS (WH0009146M1, Lot No. E5221-6D11) and rabbit anti-HRS (HPA007728, Lot No. 
A104535) (Sigma-Aldrich Company Ltd., Dorset, UK); mouse anti-HA.11 (clone 16B12; Cambridge Bioscience, 
Cambridge, UK, Lot No. B204538); goat anti-HA.11 (GTX30545, Insight Biotechnology, Lot No. 821700278); rat 
anti-HA.11 (Roche, Burgess Hill UK, Lot No. 14559100); goat or donkey anti-mouse, rat or rabbit IgG coupled to 
horseradish peroxidase, fluorescein isothiocyanate, Rhodamine Red-X, DyLight 649 or Cy5 (Stratech Scientific 
Limited, Newmarket, UK); Rat AM (Bachem, Weil am Rhein, Germany). DharmaFECT 1 Transfection Reagent, 
ON-TARGETplus HRS siRNA (J-016835-05-0002, J-016835-06-0002) and ON-TARGETplus (D-001810-10-05) 
(GE Healthcare, Little Chalfont, UK). Other reagents were from Sigma-Aldrich Company Ltd unless stated.
Plasmids. cDNA encoding rat CLR has been described14,55. cDNA encoding rat RAMP2 was obtained 
by RT-PCR from rat heart using Trizol® (Invitrogen) and Taqman Reverse Transcription reagents (Applied 
Biosystems, Warrington, UK) according to the manufacturer’s guidelines. An N-terminal Myc tag was added to 
RAMP2 by PCR. A single vector (pcDNA5/FRT) expressing both rat CLR and RAMP2 was created as described 
for CLR and RAMP114. A CLR mutant in which all predicted intracellular lysines were replaced with arginines 
(designated CLRΔ9KR) was generated using a mega-primer PCR method. Lentiviral vectors expressing either 
Figure 11. Effect of HRS overexpression on the degradation of CLR and RAMP2 following long term exposure 
to AM. (A) Cell-surface biotinylated HEK-CLR•RAMP2 cells expressing empty vector (control) or HRS were 
not treated (NT) or challenged with AM (100 nM, 16 h), biotinylated proteins immunoprecipitated (IP) and 
Western blots (WB) probed for CLR (mouse-HA, mHA), RAMP2 (mouse-Myc, mMyc) and transferrin receptor 
(TfR, loading control). In untreated cells, CLR, RAMP2 and TfR were readily detected. In control cells treated 
with AM (100 nM, 16 h) CLR and RAMP2 were significantly more degraded than in cells overexpressing HRS. 
Lysates from experimental cells were analyzed for the expression of HRS and β-actin. (B) Quantification of 
HRS expression. (C,D) Quantification of degradation of CLR and RAMP2. Data were examined using ANOVA 
and Student-Newman-Keuls post-hoc test. n = 4. *p < 0.05, **p < 0.01, ***p < 0.001. HEK-vc = HEK-vector 
control.
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CLR or CLRΔ9KR and RAMP2 were generated by releasing expression cassettes from existing plasmids by 
restriction digest, followed by cloning into a circularized pLenti6.3V5 (Invitrogen). All PCR amplified con-
structs were sequenced to verify integrity. Primer sequences are available on request. pcDNA3.0-Myc-HRS and 
Myc-HRSΔUIM were a kind gift from Professor M. von Zastrow (University of California, San Francisco, CA).
Transfected Cells and Cell Lines. Human embryonic kidney (HEK293) cells containing the Flp-In™ 
system (HEK-FLP) were from Invitrogen (Paisley, UK). Cells were cultured in Advanced Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with l-glutamine (2 mM), 2% heat-inactivated fetal bovine serum (FBS) 
and zeocin (100 μg/ml). HEK-FLP cells stably expressing CLR and RAMP2 from the same vector (pcDNA5/
FRT) were created with the Flp-In™ system according to the manufacturer’s guidelines, and cells were grown in 
Advanced DMEM supplemented with l-glutamine (2 mM), 2% heat-inactivated FBS and hygromycin B (200 µg/
ml). SV40 large T Ag-transformed human dermal microvascular endothelial cells (HMEC-156) were obtained 
from Centre for Disease Control and Prevention (Atlanta, Georgia) and were grown in MCDB131 supplemented 
with 10% heat-inactivated FBS, l-glutamine (2 mM), hydrocortisone acetate (1 µM) and human epidermal growth 
factor (10 ng/ml). HEK293T cells were grown in DMEM containing 10% heat-inactivated fetal bovine serum. All 
cells were routinely grown in 95% air, 5% CO2 at 37 °C. In control experiments, cells were stably transfected with 
vectors without inserts (HEK-vector control, HEK-vc; HMEC-1-vector control, HMEC-1-vc). In experiments 
involving expression of HRS, cells were transiently transfected using polyethylenimine (ratio 3:1 w/w).
Lentivirus Production and Transduction. HEK293T cells were plated (1 × 105 cells/cm2 in 100 mm 
dishes) and transiently transfected in DMEM/HEPES (25 mM) containing 10% heat-inactivated fetal bovine 
serum with pLenti6.3-control, pLenti6.3-CLR•RAMP2, pLenti6.3- CLRΔ9KR•RAMP2 (9 µg) together 
Figure 12. Proposed model for the regulation of CLR•RAMP2 by ubiquitination and HRS. (A) When HRS 
is expressed at endogenous levels, basal levels of CLR ubiquitination are normal and are regulated by an 
endosomal interaction with an HRS-linked E3 ligase during constitutive recycling. CLRΔ9KR is ubiquitin-
free. Upon AM-induced activation both CLR•RAMP2 and CLRΔ9KR•RAMP2 internalize to endosomes 
where CLR•RAMP2 is ubiquitinated further. Both CLR•RAMP2 and CLRΔ9KR•RAMP2 traffic to the 
multi-vesicular body (MVB), where presumably CLR•RAMP2 is deubiquitinated. CLR•RAMP2 and 
CLRΔ9KR•RAMP2 are then delivered to LAMP1-positive vesicles. (B) Depleting HRS promotes a low 
basal level of ubiquitination of CLR•RAMP2 and CLRΔ9KR•RAMP2 is ubiquitin-free. Stimulation with 
AM promotes internalization of both CLR•RAMP2 and CLRΔ9KR•RAMP2 to the MVB, CLR may then be 
ubiquitinated and deubiquitinated. CLR•RAMP2 and CLRΔ9KR•RAMP2 are then delivered to LAMP1-
positive vesicles. (C) If HRS is overexpressed the basal level of CLR ubiquitination is high due to increased 
recruitment of an E3 ligase to endosomes. AM-induced activation promotes trafficking of both CLR•RAMP2 
and CLRΔ9KR•RAMP2 to the MVB. Hyperubiquitination retards the degradation and trafficking of 
CLR•RAMP2 to LAMP1-positive vesicles, whereas non-ubiquitinated CLRΔ9KR•RAMP2 is degraded as 
normal (possibly due to incorporation of LAMP1-positive vesicles into the MVB) by trafficking to LAMP1-
positive vesicles is impeded.
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with vectors required for viral competence (pMDG.1, VSV-G envelope, 4.5 µg; pRSV.rev, HIV-1 Rev, 2.25 µg; 
pMDLg/p.RRE, packaging plasmid, 4.5 µg) using a standard calcium phosphate method for 12 hours. The 
medium was then exchanged and collected and filtered (0.45 µm) 48 h later. Viral particles were then collected by 
centrifugation (40,000 g, 6 h, 4 °C) and resuspended in HMEC-1 medium (1 ml). HMEC-1 cells (2.6 × 104 cells/
cm2 in 6-well plates) were incubated (30 min, 4 °C) with viral suspensions including polybrene (5 µg/ml). Fresh 
medium (1 ml) was added and cells incubated (overnight, 37 °C). The following days cells were washed and placed 
HMEC-1 medium for a further 48 h. HMEC-1 cells were then passaged and placed in 100 mm dishes in HMEC-1 
medium containing blasticidin (10 µg/ml). After two weeks resistant cells were pooled and cells expressing CLR at 
the cell-surface isolated using an antibody to the extracellular epitope tag (rat-HA) and Dynabeads (Invitrogen). 
Protein expression was verified by Western blotting and immunofluorescence and confocal microscopy.
Activation of CLR•RAMP2 and Drug Treatments. 48 h after plating cells or after transfection, cells 
were washed three times with PBS and placed in DMEM or MCDB131 containing 0.1% BSA (DMEM-BSA 
or MCDB131-BSA). Cells were stimulated with 100 nM rat AM for the indicated times and controls were 
left untreated for the duration of the experimental time course. Lysosomal proteases were inhibited using 
Z-Phe-Ala-diazomethylketone (Bachem, 200 µM), E64d and pepstatin A (Enzo Life Sciences, Exeter, UK; each 
10 µM) or leupeptin (Roche, 10 µM). The proteolytic activity of the proteasome was inhibited using epoxomicin 
(1 µM, Enzo Life Sciences). Controls included appropriate vehicle and inhibitors were present throughout the 
experimental time courses and added to cells 30 min prior to stimulation.
SDS-PAGE and Western Blotting. Whole cell lysates (10–30 µg protein) and immunoprecipitations 
were separated by SDS-PAGE (8, 12 or 15% acrylamide). Proteins were transferred to PVDF membranes 
(Immobilon-P, Millipore) and blocked for 1 h at room temperature (1x PBS, 0.1% Tween20, 2% BSA or 5% milk 
powder). Membranes were incubated with antibodies to pERK (1:5000), ERK2 (1:10,000), rabbit or mouse c-Myc 
(1:5-10,000), rabbit or mouse HA (1:10,000), ubiquitin (1:5000), anti-mouse HRS (1:1000), β-actin (1:100,000) 
or human transferrin receptor (1:10,000) (overnight, 4 °C; 1x PBS, 0.1% Tween20, 2% BSA or 5% milk powder). 
Membranes were washed for 30 min (1x PBS, 0.1% Tween20) and incubated with appropriate secondary anti-
bodies coupled to horseradish peroxidase (1:10,000, 1 h, room temperature). Immunoreactive proteins were 
detected using enhanced chemiluminescence (BioRad or Geneflow Ltd.). Densitometric analysis was performed 
using ImageJ software or using an ImageQuant-RT ECL imaging system (GE Healthcare) and analyzed using 
ImageQuant TL software.
Cell-Surface Biotinylation Assays. To biotinylate cell surface proteins cells were washed in 100 mM PBS, 
pH 7.4, and incubated with 0.3 mg/ml EZ-Link™-Sulfo-NHS-Biotin (Pierce) in PBS (30 min, 4 °C). Cells were 
washed in PBS, stimulated with AM (100 nM, 0-16 h in DMEM-BSA or MCDB131-BSA), lysed in RIPA buffer 
(50 mM Tris/HCl, pH 7.4, 150 mM NaCl, 5 mM MgCl2, 1 mM EGTA, 10 mM NaF, 10 mM Na4P2O7, 0.1 mM 
Na3VO4, 0.5% Nonidet P-40, peptidase inhibitor cocktail (Roche)), and centrifuged. Biotinylated proteins were 
recovered by incubation with NeutrAvidin-agarose (30 µl, overnight, 4 °C), pelleted, washed with RIPA buffer, 
boiled in Laemmli buffer, and analyzed by Western blotting.
RNA interference. HEK293 cells were plated in 12-well plates (1.2 × 105 cells/well) and left for 24 h, before 
siRNA transfections. Cells were incubated with vehicle or siRNA (25 nM)/transfection reagent complexes 
(DharmaFECT, 5 µl) for 24 h before transfection with CLR•RAMP2 using Lipofectamine2000 according to the 
manufacturer’s guidelines. Cells were used for experimentation after a further 48 h.
Immunoprecipitation. Cells were lysed in RIPA (including N-ethylmaleimide, 10 mM for HMEC-1 immu-
noprecipitations) and centrifuged (10,000 g, 20 min, 4 °C). Supernatants were rotated with immunoprecipitating 
antibody (CLR or CLRΔ9KR, 0.5 µl; rabbit c-Myc, 3 µg; rat anti-HA, 1 µg; overnight, 4 °C). Protein A/G PLUS 
(Insight Biotechnology; 30 μl) was added and samples were rotated (2 h, 4 °C). Immunoprecipitates were pelleted, 
washed with RIPA buffer, boiled in Laemmli buffer and analyzed by SDS-PAGE and Western blotting.
Immunofluorescence and Confocal Microscopy. Following drug treatments cells were washed in 100 
mm PBS, pH 7.4, and fixed in PBS containing 4% paraformaldehyde, pH 7.4 (20 min, 4 °C). Cells were washed 
with PBS containing 0.1% saponin and 2% normal horse serum for 30 min. Proteins were localized using the 
primary antibodies CLR (RK11, 1:2000), EEA1 (1:500), LAMP1 (1:1000), rabbit or mouse anti-HRS (1:100) 
(overnight, 4 °C). Cells were washed and incubated with secondary antibodies coupled to fluorescein isothiocy-
anate, rhodamine Red-X, or Cy5 (1:500, 2 h, room temperature). To examine trafficking of CLR•RAMP2 from 
the cell-surface, CLR, CLRΔ9KR and RAMP2 were labeled by incubating cells with antibodies to the extra-
cellular epitope tags (CLR, rat anti-HA, 1:1000 or goat anti-HA.11, 1:100; RAMP2, rabbit anti-c-Myc, 1:1000; 
30 min, 37 °C). Cells were washed with PBS, stimulated with AM, fixed and incubated with appropriate secondary 
antibodies. Cells were observed with a Zeiss laser-scanning confocal microscope (LSM Meta 510 or LSM 510) 
using a Plan-Apochromat 63x/1.4 Oil DIC objective. Alternatively, cells were observed with a Nikon Eclipse Ti 
laser-scanning confocal microscope using a 100x/1.45 Oil DIC N2 objective. Images were collected at a zoom 
of 1-2 and an iris of <3 μm, and at least five optical sections were taken at intervals of 0.5 μm. Single sections 
are shown. Images were processed using ImageJ and Adobe Photoshop software. Colocalization of proteins was 
determined using the NIS-Elements AR software.
Statistics. Results are expressed as mean ± S.E.M. of n ≥ 3 experiments and were compared by Student’s t 
test. Differences among multiple groups were examined using ANOVA and Student-Newman-Keuls post-hoc 
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test. *p < 0.05, **p < 0.01, ***p < 0.001 were considered to be significant. Immunofluorescence images and blots 
represent n ≥ 3 experiments.
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